• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

70岁以上老年人接种第三剂新冠病毒BBIBP-CorV和ZF2001加强疫苗后外周血单个核细胞中的抗体和转录图谱

Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine.

作者信息

Zhang Yuwei, Zhao Lianxiang, Zhang Jinzhong, Zhang Xiaomei, Han Shanshan, Sun Qingshuai, Yao Mingxiao, Pang Bo, Duan Qing, Jiang Xiaolin

机构信息

Infectious Disease Prevention and Control Section, Shandong Center for Disease Control and Prevention, Jinan, Shandong Province, China.

School of Public Health and Management, Binzhou Medical University, Yantai , Shandong Province, China.

出版信息

Immun Ageing. 2024 Jan 27;21(1):11. doi: 10.1186/s12979-023-00408-x.

DOI:10.1186/s12979-023-00408-x
PMID:38280989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10821575/
Abstract

BACKGROUND

In the context of the COVID-19 pandemic and extensive vaccination, it is important to explore the immune response of elderly adults to homologous and heterologous booster vaccines of COVID-19. At this point, we detected serum IgG antibodies and PBMC sample transcriptome profiles in 46 participants under 70 years old and 25 participants over 70 years old who received the third dose of the BBIBP-CorV and ZF2001 vaccines.

RESULTS

On day 7, the antibody levels of people over 70 years old after the third dose of booster vaccine were lower than those of young people, and the transcriptional responses of innate and adaptive immunity were also weak. The age of the participants showed a significant negative correlation with functions related to T-cell differentiation and costimulation. Nevertheless, 28 days after the third dose, the IgG antibodies of elderly adults reached equivalence to those of younger adults, and immune-related transcriptional regulation was significantly improved. The age showed a significant positive correlation with functions related to "chemokine receptor binding", "chemokine activity", and "chemokine-mediated signaling pathway".

CONCLUSIONS

Our results document that the response of elderly adults to the third dose of the vaccine was delayed, but still able to achieve comparable immune effects compared to younger adults, in regard to antibody responses as well as at the transcript level.

摘要

背景

在新冠疫情大流行和广泛接种疫苗的背景下,探索老年人对新冠病毒同源和异源加强疫苗的免疫反应很重要。此时,我们检测了46名70岁以下和25名70岁以上接种第三剂BBIBP-CorV和ZF2001疫苗参与者的血清IgG抗体和外周血单个核细胞(PBMC)样本转录组谱。

结果

在第7天,70岁以上人群接种第三剂加强疫苗后的抗体水平低于年轻人,先天免疫和适应性免疫的转录反应也较弱。参与者的年龄与T细胞分化和共刺激相关功能呈显著负相关。然而,在第三剂接种28天后,老年人的IgG抗体水平与年轻人相当,免疫相关转录调控显著改善。年龄与“趋化因子受体结合”、“趋化因子活性”和“趋化因子介导的信号通路”相关功能呈显著正相关。

结论

我们的结果表明,老年人对第三剂疫苗的反应有所延迟,但在抗体反应以及转录水平方面,仍能够与年轻人达到相当的免疫效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/4f2f9d89f23d/12979_2023_408_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/614372b7d28e/12979_2023_408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/49f908f3687a/12979_2023_408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/24e60623ec0e/12979_2023_408_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/1f21a12ff7c0/12979_2023_408_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/6746ab30c50a/12979_2023_408_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/1938561187cb/12979_2023_408_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/f0df11df0c4b/12979_2023_408_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/da0bd7f3d67e/12979_2023_408_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/cd5e5655d74b/12979_2023_408_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/4f2f9d89f23d/12979_2023_408_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/614372b7d28e/12979_2023_408_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/49f908f3687a/12979_2023_408_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/24e60623ec0e/12979_2023_408_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/1f21a12ff7c0/12979_2023_408_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/6746ab30c50a/12979_2023_408_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/1938561187cb/12979_2023_408_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/f0df11df0c4b/12979_2023_408_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/da0bd7f3d67e/12979_2023_408_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/cd5e5655d74b/12979_2023_408_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3f6/10821575/4f2f9d89f23d/12979_2023_408_Fig10_HTML.jpg

相似文献

1
Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine.70岁以上老年人接种第三剂新冠病毒BBIBP-CorV和ZF2001加强疫苗后外周血单个核细胞中的抗体和转录图谱
Immun Ageing. 2024 Jan 27;21(1):11. doi: 10.1186/s12979-023-00408-x.
2
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.RAZI 重组刺突蛋白疫苗(RCP)作为 BBIBP-CorV 初免后的加强针的免疫原性和安全性:一项平行、两组、随机、双盲试验。
BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1.
3
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.安全性、免疫原性和 mRNA 疫苗 CS-2034 作为异源加强针与 BBIBP-CorV 同源加强针在≥18 岁成年人中的效果:一项随机、双盲、2b 期临床试验。
Lancet Infect Dis. 2023 Sep;23(9):1020-1030. doi: 10.1016/S1473-3099(23)00199-8. Epub 2023 May 19.
4
Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy.使用同源或异源加强免疫策略,由第三剂BBIBP-CorV(国药集团)和BNT162b2(辉瑞-生物科技公司)疫苗引发的针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体和T细胞反应
Vaccines (Basel). 2022 Mar 30;10(4):539. doi: 10.3390/vaccines10040539.
5
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.接种两剂 BBIBP-CorV 疫苗后单剂 Ad26.COV2.S 加强针对成年人 SARS-CoV-2 感染的效果:一项 1/2 期开放标签试验的第 28 天结果。
Vaccine. 2023 Jul 19;41(32):4648-4657. doi: 10.1016/j.vaccine.2023.06.043. Epub 2023 Jun 15.
6
Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older.BBIBP-CorV 和 ZF2001 异源加强免疫对 18 岁及以上健康成年人的 SARS-CoV-2 的安全性、免疫原性和免疫持久性。
Expert Rev Vaccines. 2023 Jan-Dec;22(1):1079-1090. doi: 10.1080/14760584.2023.2274491. Epub 2023 Nov 8.
7
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.两剂BBIBP-CorV疫苗后接种一剂病毒载体和mRNA新冠疫苗作为加强针在已接种两剂BBIBP-CorV疫苗的成年初免者中针对Delta和Omicron变异株的免疫原性
Vaccines (Basel). 2022 Jul 3;10(7):1071. doi: 10.3390/vaccines10071071.
8
Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals.COVID-19 基础-加强免疫接种的安全性和有效性:同源 BBIBP-CorV 与异源 BNT162b2 加强剂在 BBIBP-CorV 基础免疫人群中的效果。
Vaccine. 2023 Mar 17;41(12):1925-1933. doi: 10.1016/j.vaccine.2023.01.032. Epub 2023 Jan 23.
9
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.成年人接种同源和异源加强疫苗后的免疫反应和转录谱。
Front Immunol. 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024.
10
Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.同源加强免疫接种灭活疫苗可在医务人员中引起强烈的抗体反应:一项回顾性研究。
Front Immunol. 2023 Feb 3;14:1099629. doi: 10.3389/fimmu.2023.1099629. eCollection 2023.

引用本文的文献

1
Transcriptome Profiles Characteristics of the Peripheral Immune in Patients with Severe Fever with Thrombocytopenia Syndrome.发热伴血小板减少综合征患者外周免疫的转录组特征
J Inflamm Res. 2024 Nov 7;17:8357-8374. doi: 10.2147/JIR.S485118. eCollection 2024.
2
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.成年人接种同源和异源加强疫苗后的免疫反应和转录谱。
Front Immunol. 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024.

本文引用的文献

1
IgG anti-RBD levels during 8-month follow-up post-vaccination with BNT162b2 and mRNA-1273 vaccines in healthcare workers: A one-center study.接种 BNT162b2 和 mRNA-1273 疫苗后 8 个月内医护人员 IgG 抗 RBD 水平:一项单中心研究。
Front Cell Infect Microbiol. 2022 Nov 30;12:1035155. doi: 10.3389/fcimb.2022.1035155. eCollection 2022.
2
Humoral immunity and transcriptome differences of COVID-19 inactivated vacciane and protein subunit vaccine as third booster dose in human.人体第三剂加强针中 COVID-19 灭活疫苗和蛋白亚单位疫苗的体液免疫和转录组差异。
Front Immunol. 2022 Oct 21;13:1027180. doi: 10.3389/fimmu.2022.1027180. eCollection 2022.
3
Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.
人类对 13 种疫苗的免疫反应转录图谱揭示了一种预测疫苗诱导抗体反应的共同指标。
Nat Immunol. 2022 Dec;23(12):1788-1798. doi: 10.1038/s41590-022-01328-6. Epub 2022 Oct 31.
4
Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.老年人接种 BNT162b2 疫苗后针对 SARS-CoV-2 WT 和 Delta 变异株的免疫应答。
Front Immunol. 2022 Jun 27;13:868361. doi: 10.3389/fimmu.2022.868361. eCollection 2022.
5
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose.老年人对两剂 COVID-19 mRNA 疫苗的体液反应持久性较低,但对第三剂的初始反应较强。
J Infect Dis. 2022 Sep 21;226(6):983-994. doi: 10.1093/infdis/jiac199.
6
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron.COVID-19 康复后 15 个月和 20 个月对 80 岁以上人群进行 mRNA 疫苗接种可引发强烈的免疫和抗体反应,其中包括奥密克戎。
Cell Rep. 2022 Apr 12;39(2):110680. doi: 10.1016/j.celrep.2022.110680. Epub 2022 Mar 25.
7
T cell immunity to SARS-CoV-2.T 细胞对 SARS-CoV-2 的免疫。
Semin Immunol. 2021 Jun;55:101505. doi: 10.1016/j.smim.2021.101505. Epub 2021 Oct 21.
8
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing.衰老三重困境:COVID-19、合并症和炎症衰老。
Ageing Res Rev. 2022 Jan;73:101494. doi: 10.1016/j.arr.2021.101494. Epub 2021 Oct 22.
9
clusterProfiler 4.0: A universal enrichment tool for interpreting omics data.clusterProfiler 4.0:用于解释组学数据的通用富集工具。
Innovation (Camb). 2021 Jul 1;2(3):100141. doi: 10.1016/j.xinn.2021.100141. eCollection 2021 Aug 28.
10
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.使用BNT162b2疫苗第三剂对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)进行中和
N Engl J Med. 2021 Oct 21;385(17):1627-1629. doi: 10.1056/NEJMc2113468. Epub 2021 Sep 15.